Source comparison
CJC-1295 for Joint Pain Research Evidence: Comparison Across GH Pathways
CJC-1295 (with DAC) GHRH analogue. Extends endogenous GH pulses 6–8 days Indirect. Rodent cartilage studies show collagen synthesis; no human joint trials Twice weekly (1–2mg per dose) No published human trials targeting joint pathology; dose extrapolation fro
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- GHRH analogue. Extends endogenous GH pulses
- 6–8 days
- Indirect. Rodent cartilage studies show collagen synthesis; no human joint trials
- Twice weekly (1–2mg per dose)
- No published human trials targeting joint pathology; dose extrapolation from animal models unclear
- Ipamorelin
- Ghrelin mimetic. Stimulates GH release via GHSR-1a receptor
- 2 hours
- None. Used primarily for GH elevation, not tissue-specific repair
- Daily or twice daily (200–300µg per dose)
- Requires frequent dosing; no cartilage repair data; mechanism bypasses IGF-1 in some pathways
- BPC-157
- Synthetic pentadecapeptide. Modulates growth factor expression
- 4–6 hours (estimated)
- Tendon and ligament healing in rodent models; anecdotal joint pain reports
- Daily (200–500µg per dose, subcutaneous or oral)
- No human clinical trials; mechanism poorly characterised; FDA has issued warnings on unapproved use
- Recombinant hGH (somatropin)
- Direct GH replacement. Bypasses pituitary regulation
- 3–4 hours
- Modest cartilage thickness gains in GH-deficient adults; 0.18mm femoral cartilage increase over 12 months
- Daily subcutaneous injection (0.3–0.6mg/day)
- Supraphysiologic dosing risks insulin resistance and joint swelling; expensive; requires prescription for non-research use
- TB-500 (Thymosin Beta-4 fragment)
- Actin-binding peptide. Promotes cell migration and angiogenesis
- 10 days
- Wound healing and muscle repair in animal models; no controlled joint studies
- Twice weekly (2–5mg per dose)
- Minimal human data; joint-specific effects unvalidated; primarily studied for soft tissue injury
- Professional Assessment
- CJC-1295 offers the most plausible mechanism for cartilage repair among peptides due to sustained IGF-1 elevation, but lacks dedicated joint trials. BPC-157 has anecdotal support but zero human evidence. Recombinant GH has the strongest clinical data but comes with metabolic side effects. The field needs bridging trials. None exist yet.